## ACTIVATING THE IMMUNE SYSTEM TO FIGHT CANCER

ONCOS-102 Trial updates

December 2, 2020

targovax

## **IMPORTANT NOTICE AND DISCLAIMER**

This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in future and which, by their nature, will have an impact on the results of operations and the financial condition of Targovax. Such forward-looking statements reflect the current views of Targovax and are based on the information currently available to the company. Targovax cannot give any assurance as to the correctness of such statements.

There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the success of future clinical trials; risks relating to personal injury or death in connection with clinical trials or following commercialization of the company's products, and liability in connection therewith; risks relating to the company's freedom to operate (competitors patents) in respect of the products it develops; risks of non-approval of patents not yet granted and the company's ability to adequately protect its intellectual property and knowhow; risks relating to obtaining regulatory approval and other regulatory risks relating to the development and future commercialization of the company's ability to successfully commercialize and gain market achieve commercial success; risks relating to the future development of the pricing environment and/or regulations for pharmaceutical products; risks relating to the company's ability to secure additional financing in the future, which may not be available on favorable terms or at all; risks relating to currency fluctuations; risks relating to the company's ability to retain key personnel; and risks relating to the impact of competition.



# Introduction


- 2. Melanoma
- 3. Mesothelioma
- 4. Q&A



## MEDICAL NEED FOR IMMUNE ACTIVATORS

CPIs are revolutionizing cancer therapy... ...but only a minority of patients respond...

...leading to a high medical need for immune activators



1 Immune Checkpoint Inhibitors Markets Report, 2020 January, ResearchAndMarkets.com

4 2 Estimation of the Percentage of U.S. Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, JAMA Netw Open. 2019 May; 2(5), Haslam A., Prasad V.



## PIPELINE WITH RICH NEAR-TERM NEWS FLOW

Product candidate	Preclinical	Phase 1	Phase 2	Collaborator	Next expected event
ONCOS-102	Mesothelioma Combination w/ pemetrexed/cisplatin		Sector Merck	<b>1H 2021</b> 24-month survival	
	<b>Melanoma</b> Combination w/Keytruda				DATA TODAY
	<b>Colorectal</b> Combination w/Imfinzi			AstraZeneca	Update by collaborator
	Prostate Combination w/DCvac			Sotio	Update by collaborator
ONCOS-200 series	Next Gen viruses			leidos	Updates at conferences
Novel mutRAS concepts				VALO THERAPEUTICS	





# Melanoma


- 3. Mesothelioma
- 4. Q&A



## ONCOS-102 IN ANTI-PD1 REFRACTORY MELANOMA

Patient population	<ul> <li>Advanced, unresectable melanoma</li> <li>Disease progression despite prior treatment with anti-PD1</li> <li>20 patients, 11 stage III and 9 stage IV</li> <li>Poor prognosis, with few treatment alternatives</li> </ul>
<b>Clinical centers</b>	<ul> <li>Lead: Memorial Sloan Kettering Cancer Center (New York City)</li> <li>University of Maryland Comprehensive Cancer Center (Baltimore)</li> <li>Fox Chase Cancer Center (Philadelphia)</li> <li>Oslo University Hospital (Oslo)</li> <li>ClinicalTrials.gov Identifier: NCT03003676</li> </ul>
Treatment regime	<ul> <li>Part 1: 3 ONCOS-102 injections followed by 5 months of Keytruda</li> <li>Part 2: 12 ONCOS-102 injections; priming and concomitant use</li> </ul>

## MELANOMA TRIAL DESIGN




CPO: Cyclophosphamide




## PATIENT DEMOGRAPHICS – MORE ADVANCED DISEASE IN PART 2

Parameters	Part 1 (n=8)	Part 2 (n=12)	Total (N=20)
Median time from diagnosis to start ONCOS-102 (years)	6.9	2.9	4.5
Average number of checkpoint inhibitor treatments prior to study	1.8	2.3	2.2
Average number of lesions at baseline	4.5	9.1	7.3
Average tumor burden targeted lesions at baseline (mm)	50.3	66.1	58.2
Stage of patients - III - IV	6 2	5 7	11 9



## 7 OF 20 PATIENTS WITH PARTIAL OR COMPLETE RESPONSE RESULTS IN ORR OF 35%


Best change in tumor burden from baseline, percent



Response defined as tumor reduction of at least 30% in at least one CT scan, according to RECIST 1.1
 Preliminary data




## MULTIPLE EXAMPLES OF SYSTEMIC (ABSCOPAL) EFFECT TWO PATIENTS WHERE A NON-INJECTED LESION COMPLETELY DISAPPEARED



- Findings are based on **early data** assessment, systemic effects will be further assessed
- Used threshold of tumor reduction of 30%<sup>1</sup> or more in a lesion
- Observed in patients in both Part 1 and 2
- Complete remission of non-injected lesion seen in two patients



## ONCOS-102 EFFICACY IS COMPETITIVE TO LEADING DRUG CANDIDATES IN ANTI-PD1 REFRACTORY MELANOMA



Targovax market analysis, November 2020.

# EXCELLENT CLINICAL DATA SUPPORT CONTINUED DEVELOPMENT IN ANTI-PD1 REFRACTORY MELANOMA



#### **Excellent safety profile confirmed**

• ONCOS-102 and Keytruda combination is well-tolerated



#### **Excellent clinical outcome**

- 35% ORR: Tumor responses were observed in 7 out of 20 evaluable patients
- **Systemic effect:** Tumor regression in non-injected lesions observed in multiple patients, including two lesions that regressed completely
- Confirmed ONCOS-102 ability to reactivate CPI refractory tumors



#### Next steps

- Planning for a confirmatory melanoma trial in combination with anti-PD1 checkpoint inhibitor
- Analyze more **immunological data**



# Mesothelioma

4. Q&A



### HIGH NEED FOR NEW TREATMENT APPROACHES IN MALIGNANT PLEURAL MESOTHELIOMA



#### Surgery

Only 10% of patients suitable for resection Often diagnosed too late for surgery Technically challenging

#### Radiotherapy

Rarely effective due to tumor shape Hard to focus radiation Mainly palliative care





#### Chemotherapy

Standard of care (SoC) with limited efficacy

Only approved option is pemetrexed/cisplatin


6 months mPFS and 12 months mOS in 1<sup>st</sup> line

#### Immunotherapy

Ipi/nivo approved in 1<sup>st</sup> line disease (US only)

CPIs included in NCCN guidelines as 2<sup>nd</sup> line option

CPI + SoC trials ongoing






# ADVANCED MALIGNANT PLEURAL MESOTHELIOMA PHASE I/II TRIAL IN COMBINATION WITH CHEMO

#### Trial design

- First and second (or later) line
- Standard of Care (SoC)
   Chemo: Pemetrexed and cisplatin, 6 cycles
- ONCOS-102: 6 intra-tumoral injections




# PROMISING SURVIVAL IN FIRST LINE PATIENTS

ITT: N = 31 (20+11) PP: N = 30 (19+11)	ONCOS-102 + SoC Safety lead-in n = 6	ONCOS-102 + SoC Randomized n = 14	SoC only control Randomized n = 11	Comments
First line patients (number)	3	8	6	No previous chemotherapy
Median Progression Free Survival (mPFS)	8.4 months	9.8 months	7.6 months	
18-month survival rate (percentage)	33%	63%	33%	
Median Overall Survival (mOS)	11.0 months	≥ 18.2 months	≤ 14.2 months	mOS not yet reached in the randomized experimental group
Second (or later) line patients (number)	3	6	5	Received previous chemotherapy
Median Progression Free Survival (mPFS)	1.9 months	7.4 months	8.5 months	
Median Overall Survival (mOS)	5.0 months	14.4 months	≥ 19.5 months	





17 ITT: Intention to treat PP: Per protocol


## FIRST LINE DATA ARE MATURING AND ALREADY COMPETITIVE -MOS WILL BE 18.2 MONTHS OR MORE




8 1L randomized patients mOS will change: Experimental group, 8 patients (5 censored). Control group, 6 patients (2 censored)









# CLINICAL AND IMMUNE DATA SUPPORT TRIPLE COMBINATION WITH CHECKPOINT INHIBITOR



#### **Excellent safety profile confirmed**

• ONCOS-102 and SoC chemotherapy combination is well-tolerated



#### **Clear clinical activity**

- mOS not yet reached but at least 18.2 months
- mPFS of 9.8 months in first line randomized ONCOS-102 treated patients
- Broad and powerful **immune activation** associated with **clinical benefit**



#### Next steps

- First line identified as target population for further development
- Strong rationale for combination with anti-PD1/L1 checkpoint inhibitor and SoC chemotherapy - Collaboration established with Merck

